Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen announces local availability of Lilly’s Mounjaro

Aspen is in a closed period from 1st July 2025 until the publication of the annual results on the JSE SENS platform on the 3rd September 2025.
Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600
Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa